CY1107939T1 - Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη - Google Patents

Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη

Info

Publication number
CY1107939T1
CY1107939T1 CY20081100487T CY081100487T CY1107939T1 CY 1107939 T1 CY1107939 T1 CY 1107939T1 CY 20081100487 T CY20081100487 T CY 20081100487T CY 081100487 T CY081100487 T CY 081100487T CY 1107939 T1 CY1107939 T1 CY 1107939T1
Authority
CY
Cyprus
Prior art keywords
prevention
diabetes
synoptic
treatment
medicinal drugs
Prior art date
Application number
CY20081100487T
Other languages
English (en)
Inventor
Zoltan SZILVÁSSY
György Rabloczky
NAGY Peter LITERÁTI
Original Assignee
N-Gene Research Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N-Gene Research Laboratories Inc. filed Critical N-Gene Research Laboratories Inc.
Publication of CY1107939T1 publication Critical patent/CY1107939T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

Η εφεύρεση αναφέρεται σε ένα συνεργικό φαρμακευτικό συνδυασμό που αποτελείται από (a) μία πρώτη φαρμακευτική σύνθεση περιέχουσα έναν αντιδιαβητικό ή αντι-υπερλιπιδαιμικό δραστικό παράγοντα και έναν ή περισσότερους συμβατικό(ούς) φορέα(είς), και (b) μία δεύτερη φαρμακευτική σύνθεση περιέχουσα ένα παράγωγο υδροξιμικού οξέως τύπου I και έναν ή περισσότερους συμβατικό(ούς) φορέα(είς). Ο φαρμακευτικός συνδυασμός είναι κατάλληλος για την πρόληψη, μεταξύ άλλων, του σακχαρώδη διαβήτη.
CY20081100487T 2001-07-17 2008-05-08 Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη CY1107939T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
EP02751454A EP1408966B1 (en) 2001-07-17 2002-07-10 Synergistic pharmaceutical combinations for the prevention or treatment of diabetes

Publications (1)

Publication Number Publication Date
CY1107939T1 true CY1107939T1 (el) 2013-09-04

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100487T CY1107939T1 (el) 2001-07-17 2008-05-08 Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη

Country Status (21)

Country Link
US (2) US7635674B2 (el)
EP (1) EP1408966B1 (el)
JP (1) JP4598390B2 (el)
KR (1) KR100920560B1 (el)
CN (1) CN1270713C (el)
AT (1) ATE386523T1 (el)
AU (1) AU2002354884B2 (el)
BR (1) BR0210744A (el)
CA (2) CA2452558C (el)
CY (1) CY1107939T1 (el)
DE (1) DE60225143T2 (el)
DK (1) DK1408966T3 (el)
ES (1) ES2300460T3 (el)
IL (2) IL159412A0 (el)
MX (1) MXPA04000324A (el)
NO (1) NO20040153L (el)
NZ (1) NZ531155A (el)
PL (1) PL205826B1 (el)
PT (1) PT1408966E (el)
RU (1) RU2311907C2 (el)
WO (1) WO2003007951A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807093A2 (en) * 2004-10-13 2007-07-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
UA96311C2 (ru) * 2006-11-02 2011-10-25 Н-Джин Ресерч Лабораторис Инк. Фармацевтическая композиция, которая имеет антипсихотическую, антидепрессантную или противоэпилептическую активность, со сниженным побочным эффектом
UA96312C2 (ru) * 2006-11-02 2011-10-25 Н-Джин Ресерч Лабораторис Инк. Применение о-(3-пиперидино-2-гидрокси-1-пропил)никотинамидоксима для уменьшения чрезмерной массы тела или ожирения
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
JO3272B1 (ar) 2007-07-19 2018-09-16 Takeda Pharmaceuticals Co مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد
ES2638977T3 (es) * 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
JP5951752B2 (ja) 2011-04-13 2016-07-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｐｔｐ１ｂ発現のアンチセンス調節
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
JP7221227B2 (ja) 2017-06-30 2023-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発毛を調節するための組成物及び方法
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
KR20230016661A (ko) * 2020-05-27 2023-02-02 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c9 기질의 병용 투여

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
ATE386523T1 (de) 2008-03-15
AU2002354884B2 (en) 2007-10-18
EP1408966A1 (en) 2004-04-21
EP1408966B1 (en) 2008-02-20
BR0210744A (pt) 2004-07-20
KR100920560B1 (ko) 2009-10-08
PL364662A1 (en) 2004-12-13
IL159412A (en) 2009-09-22
NO20040153L (no) 2004-03-16
RU2004105149A (ru) 2005-04-20
AU2002354884A2 (en) 2003-03-03
MXPA04000324A (es) 2004-07-23
US20070015687A1 (en) 2007-01-18
US7635674B2 (en) 2009-12-22
DK1408966T3 (da) 2008-06-16
IL159412A0 (en) 2004-06-01
CA2452558C (en) 2009-12-22
RU2311907C2 (ru) 2007-12-10
CA2452558A1 (en) 2003-01-30
KR20040029371A (ko) 2004-04-06
PL205826B1 (pl) 2010-05-31
NZ531155A (en) 2005-07-29
CN1270713C (zh) 2006-08-23
WO2003007951A1 (en) 2003-01-30
CN1531433A (zh) 2004-09-22
ES2300460T3 (es) 2008-06-16
JP2004537550A (ja) 2004-12-16
JP4598390B2 (ja) 2010-12-15
CA2682251A1 (en) 2003-01-30
DE60225143T2 (de) 2009-02-12
US8048873B2 (en) 2011-11-01
PT1408966E (pt) 2008-05-02
US20100048627A1 (en) 2010-02-25
DE60225143D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
CY1107939T1 (el) Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
CY1107966T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
NO20052908L (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
PT1251846E (pt) Taxanos com carbonato c-4
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
SE0004827D0 (sv) Therapeutic compounds
DE60023154D1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
RU2217420C1 (ru) 2-r-7а-метил-3-(спироциклогекса-2,5-диен-4-он)-пергидроиндолины-1
ATE241604T1 (de) Polyhydroxyalkylpyrazine derivate und deren herstellung und diese enthaltende arzneimittel
BR0211026A (pt) Medicamentos que contem derivados de tetrahidroquinolina
UA81608C2 (ru) Синергическая фармацевтическая комбинация для профилактики или лечения диабета